After gains of 5.9% this afternoon, Exact Sciences shares are now trading at $59.4. Read below for the essential facts about this stock:
-
Exact Sciences has logged a -21.5% 52 week change, compared to 24.2% for the S&P 500
-
EXAS has an average analyst rating of buy and is -17.34% away from its mean target price of $71.86 per share
-
Its trailing earnings per share (EPS) is $-1.16, which brings its trailing Price to Earnings (P/E) ratio to -51.2. The Health Care sector's average P/E ratio is 26.07
-
The company's forward earnings per share (EPS) is $-0.34 and its forward P/E ratio is -174.7
-
The company has a Price to Book (P/B) ratio of 3.42 in contrast to the Health Care sector's average P/B ratio is 3.53
-
The current ratio is currently 2.3, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $31.93 Million and the average free cash flow growth rate is 2.8%
-
Exact Sciences's revenues have an average growth rate of 30.3% with operating expenses growing at 28.3%. The company's current operating margins stand at -8.6%